Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Natural Killer Cell Therapy · 1 trial · 3 indications
Immunohistochemical and in vitro studies of tissue from the original biopsy and post-NK cell treated tumor specimens will be performed to assess NK cell infiltration of the tumor. Difference in NK cell density by CD56 staining in pre- versus post-intervention skin tumor tissue will be compared between tumors receiving NK versus transforming growth factor betai cell injections.
| Arm | Type | Description |
|---|---|---|
| Cohort I (UD expanded NK cells) | EXPERIMENTAL | Patients undergo SOC biopsy on day 0 and within 4 weeks (days 10-28) receive UD expanded NK cells intratumorally. Patients undergo SOC excision 4-8 weeks (days 28-56) after biopsy. |
| Cohort II (UD expanded TGFbetai NK cells) | EXPERIMENTAL | Patients undergo SOC biopsy on day 0 and within 4 weeks (days 10-28) receive UD expanded TGF-beta-i NK cells intratumorally. Patients undergo SOC excision 4-8 weeks (days 28-56) after biopsy. |
| Name | Type | Description |
|---|---|---|
| Biopsy Procedure | PROCEDURE | Undergo SOC biopsy |
| Natural Killer Cell Therapy | BIOLOGICAL | Given UD expanded NK cells intratumorally |
| Surgical Procedure | PROCEDURE | Undergo SOC excision |
| Universal Donor Expanded TGF-beta-imprinted NK Cells | BIOLOGICAL | Given intratumorally |
Inclusion Criteria: * Ohio State University patients \> 18 years old * Diagnosis of ≥ 1cm keratinocyte carcinoma, accessible by intra-tumoral injection * Confirmation of cutaneous SCC (cSCC) (10 patients total) or BCC (10 patients total) via diagnostic biopsy * BCC: Nodular or aggressive subtype...
Natural Killer Cell Therapy is an investigational monoclonal antibody being studied for the treatment of Skin Basal Cell Carcinoma. It is administered through intratumoral injection and is currently in early Phase 1 clinical development. The therapy is being evaluated in a controlled trial with biomarker selection, though it is not yet approved.
Johnson & Johnson (NYSE: JNJ) is developing Natural Killer Cell Therapy. The company is conducting a Phase 1 clinical trial for this investigational treatment targeting Skin Basal Cell Carcinoma. Johnson & Johnson is the sponsor of the ongoing study, which is currently recruiting participants in the United States.
Natural Killer Cell Therapy is in early Phase 1 clinical development. It is an investigational therapy, meaning it has not been approved by regulatory authorities. The ongoing trial is actively recruiting participants and is designed as a controlled study with biomarker selection for the treatment of Skin Basal Cell Carcinoma.
Natural Killer Cell Therapy is being studied in clinical trial NCT07144384, titled "Intratumoral Injection of Standard Universal Donor Expanded Natural Killer Cells and TGF-beta Imprinted Natural Killer Cells for the Treatment of Skin Squamous Cell Carcinoma and Basal Cell Carcinoma." This early Phase 1 trial is recruiting 40 participants in the United States.
Natural Killer Cell Therapy is a monoclonal antibody designed to target and modulate natural killer cells. It is administered via intratumoral injection to treat Skin Basal Cell Carcinoma. The therapy is being evaluated for its ability to enhance the immune response against tumor cells, though the specific molecular target has not been disclosed.